Engineering Magnetosomes for High-Performance Cancer Vaccination
Engineering Magnetosomes for High-Performance Cancer Vaccination
复制标题
工程磁小体用于高性能癌症疫苗接种
DOI：
10.1021/acscentsci.9b00060
复制
发表时间：
2019-05-22
影响因子：
18.2
通讯作者：
Xie, Hai-Yan
中科院分区：
文献类型：
--
作者：
Li, Feng;Nie, Weidong;Xie, Hai-Yan
以Fe3O4磁性纳米簇（MNCs）为核心，以抗cd205修饰的癌细胞膜为外衣，研制了一种新型癌症疫苗。由于跨国公司的超顺磁性和磁化性，它首先实现了疫苗在淋巴结中的磁保留与磁共振成像（MRI）指南，这打开了树突状细胞（DCs）吸收抗原的时间窗口。同时，伪装的癌细胞膜作为各种抗原的储存库，使后续的多抗原反应成为可能。此外，修饰后的抗cd205将更多的疫苗导入CD8(+) dc，促进主要组织相容性复合体（MHC） I交叉呈递。这些独特的优势共同导致T细胞的大量增殖，具有优越的克隆多样性和细胞毒性活性。结果，在五种不同的肿瘤模型中观察到有效的预防和治疗效果，几乎没有异常。因此，这种结合了各种最新纳米技术的癌症衍生磁小体成功地证明了它在安全和高性能癌症疫苗接种方面的前景。
A novel cancer vaccine is developed by using Fe3O4 magnetic nanoclusters (MNCs) as the core and cancer cell membranes decorated with anti-CD205 as the cloak. Because of the superparamagnetism and magnetization of MNCs, it is first achieved for the magnetic retention of vaccine in the lymph nodes with a magnetic resonance imaging (MRI) guide, which opened the time window for antigen uptake by dendritic cells (DCs). Meanwhile, the camouflaged cancer cell membranes serve as a reservoir of various antigens, enabling subsequent multiantigenic response. Additionally, the decorated anti-CD205 direct more vaccine into CD8(+) DCs, facilitating the major histocompatibility complex (MHC) I cross-presentation. These unique advantages together lead to a great proliferation of T cells with superior clonal diversity and cytotoxic activity. As a result, potent prophylactic and therapeutic effects with few abnormalities are observed on five different tumor models. Therefore, such a cancer-derived magnetosome with the integration of various recent nanotechnologies successfully demonstrates its promise for safe and high-performance cancer vaccination.